U.S. markets open in 5 hours 21 minutes

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.1945-0.0155 (-1.28%)
At close: 3:59PM EDT
Sign in to post a message.
  • J
    Joey Angels
    Just the facts…, Northwest Biotherapeutics
    Northwest Biotherapeutics (OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more "audacious" than that of the previous companies.

    The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company "phase-shifted" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.

    The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that "no interim analysis of efficacy in the Phase III trial [had] been done." What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.

    The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.

    Last October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.

    Shareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.
  • J
    Joey Angels
    Northwest Biotherapeutics
    Northwest Biotherapeutics (OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more "audacious" than that of the previous companies.

    The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company "phase-shifted" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.

    The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that "no interim analysis of efficacy in the Phase III trial [had] been done." What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.

    The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.

    Last October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.

    Shareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.
  • M
    Mary
    Linda F. Ponzi and Ana’s on other boards trashing legitimate cancer bio’s. Desperate as it gets…
    Keith&KatrinaKeith&Katrina25 minutes ago
    The reclassification of nGBM and rGBM signals the death null of this company. Immunotherapy about to be King in this space. The investors who truly understand the science are bailing in their droves.
  • L
    LearningCurve2020
    Still wondering why the company or Hub Club haven't insisted that Mr. Sun correct his article?? Deep down I think we know why.

    >>The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded.
  • R
    RichardUpward
    With the inevitable death cross loaming over $NWBO a couple things to keep in mind. There are 100's of millions of options and warrants well in the money that are slowly cashing in on a weekly basis with no end in sight. If the pending financing rumor is true, that will add to the dilution.
  • J
    Jill
    Dboob contemplating his investment In NWBO.
  • L
    LearningCurve2020
    Clearly the "people" here have the same message control strategy as over on the Hub. Funny how that works.
  • R
    RichardUpward
    I am hearing chatter about a preferred offering in the works, followed shortly by a vote on increasing the shelf. Sadly it appears more dilution is on the way .
    Bearish
  • L
    LearningCurve2020
    >>The National Institutes of Health has doled out nearly $46 million in taxpayer funds to 100 Chinese institutions in the form of subgrants since fiscal year 2012, federal data shows.

    -Daily C
  • M
    Mary
    Xonixt359, “a”, Jean, Matt, MichaelK & N, Keith & Katerina the walls are closing in. With that have a nice day.
  • M
    Mary
    I can’t figure out why people post that they have allegedly increased their position every time NWBO tanks. Are they looking for special recognition?
  • J
    James
    Unfortunately Capitulation is upon us. Too many longs thinning out their shares. In addition there seems to be little to no buying interest in NWBO at the moment. At this point in time
    we can only hope there is some (ANY) news to move this company's technology forward.
    As a long time holder, even I am not as optimistic as I once was, lets face it, it's taken an awful long time. Company has had it's share of negativity in abundance.
    Neutral
  • J
    Jill
    Dboob with NWBO Ponzi cabal coming to a theater near you.
  • L
    LearningCurve2020
    Can't help but to notice many similarities over there.

    “That’s Not Happening and It’s Good That It Is”

    Find it quickly.
  • T
    TheeJew
    when people used to ask me what will this be worth if approved I used to say if a d that's a big if I see $ 2.35 but now considering how low its gone i think $1.80 is my new target 50 % from here ain't bad ...again. with a big ...if
  • L
    LearningCurve2020
    Maybe a Big Biz Show interview to give retail a shot in the arm. LG can explain why things are delayed indefinitely. lol.
  • J
    Joey Angels
    Very high volume, looks like someone’s liquidating their position. Almost all buys are met by sells. Is Linda F. Ponzi & hubby Hemphill buying another home or is Lappin cashing in?
  • D
    Danielle
    Sold 90% of my position, complete order not executed yet, show very low buying trend, this is not looking good, will dive further unless management issues a PR addressing the delay..
  • L
    LearningCurve2020
    This is exactly how it went over on Oncbiomune and Peregrind. Hub Club censored me then the stock crashed.
  • L
    LearningCurve2020
    Hubers always talk about Woodford but they miss the real story. There's likely a reason everyone was hiring investigators with security clearances.